Personalis experienced a challenging second quarter in 2025 with a significant revenue decline of 24% year-over-year, primarily due to expected decreases from Natera and a reduction in pharma tests and services. Despite these headwinds, the company demonstrated strong clinical adoption, with a 59% sequential increase in clinical test volume, driven by the NeXT Personal® platform and compelling clinical data presentations. The net loss widened compared to the previous year, and the gross margin decreased.

Personalis, Inc. reported first quarter 2025 revenue of $20.6 million, a 6% increase year-over-year, primarily due to strong growth in pharma tests and services. The company delivered 2,184 total molecular tests, a 52% sequential increase, and reported a net loss of $15.8 million.

Personalis, Inc. reported a fourth quarter 2024 revenue of $16.8 million, a 15% decrease from the prior year, primarily due to expected declines from Natera and VA MVP. Despite the revenue decrease, the company significantly reduced its net loss to $16.4 million from $26.6 million in the same period last year. The company also highlighted a strategic investment of $50 million from Merck and an expanded partnership with Tempus AI.

Personalis reported a 41% year-over-year increase in revenue, driven by a 96% increase in biopharma revenue. The company raised its 2024 revenue guidance and secured significant financing, extending its cash runway into the first half of 2027.

Personalis reported a 35% year-over-year increase in total company revenue, driven by a 117% increase in revenue from biopharma business. The company also delivered 561 total molecular tests, a 66% increase compared to the prior quarter. They raised the full year revenue guidance for 2024.

Personalis reported strong execution in Q1 2024, exceeding revenue guidance with $19.5 million and demonstrating progress in NeXT Personal clinical evidence development.

Personalis, Inc. reported an 18% increase in revenue for the fourth quarter of 2023, reaching $19.7 million compared to $16.7 million in the fourth quarter of 2022. Revenue growth was primarily driven by pharma tests, enterprise sales, and other customers, which increased to $18.7 million from $15.8 million in the prior year. However, the company reported a net loss of $26.6 million, or $0.54 per share, compared to a net loss of $31.1 million, or $0.67 per share, for the fourth quarter of 2022.

Personalis, Inc. reported a 23% increase in third quarter revenue to $18.2 million compared to the same period last year. The company presented data supporting Next Personal’s market leading sensitivity for cancer recurrence detection and increased full year guidance.

Personalis reported a total revenue of $16.7 million for Q2 2023, an 8% decrease compared to Q2 2022. The company is focusing on expanding its biopharma opportunities and plans to launch its MRD test later this year.

Personalis, Inc. reported a 24% increase in revenue for the first quarter of 2023, driven by growth in pharma tests and enterprise sales. The company is focused on expanding its presence in the MRD space, enabling personalized cancer vaccine development, and supporting biopharmaceutical customers with clinical trials.

Personalis reported Q4 2022 revenue of $16.7 million and a net loss of $31.1 million. The company is focusing on MRD, personalized cancer vaccines, and supporting pharmaceutical clinical trials.

Personalis reported a revenue of $14.9 million for Q3 2022, a decrease compared to Q3 2021. However, revenue from biopharma and other customers, excluding the VA MVP, increased by 73%. The company continues to focus on strategic priorities and collaborations to advance precision oncology.

Personalis, Inc. reported a decrease in revenue for the second quarter of 2022 compared to the same period in 2021. Total revenue was $18.2 million, compared to $21.7 million in Q2 2021. However, revenue from biopharma and other customers, excluding the VA MVP, increased by 74%. The company's net loss was $27.5 million, or $0.60 per share.

Personalis reported a revenue of $15.2 million for Q1 2022, a decrease compared to $20.9 million in Q1 2021. The decrease was primarily due to a decline in revenue from the VA MVP program, offset by an increase in revenue from biopharma and other customers. Net loss for the quarter was $28.2 million, or $0.63 per share.

Personalis, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021. The company's quarterly revenue increased by 3% compared to the fourth quarter of 2020. Revenue from biopharma and other customers, excluding the VA MVP, increased by 102%.

Personalis, Inc. reported financial results for the third quarter ended September 30, 2021, with a revenue of $22.3 million, a 12% increase compared to the third quarter of 2020. The company's revenue from oncology customers grew 50% over the same period last year. Personalis is preparing to launch NeXT Personal, its Minimal Residual Disease (MRD) offering in December.

Personalis, Inc. reported record quarterly revenue of $21.7 million, an 11% increase compared to the second quarter of 2020. Revenue from biopharma and all other customers grew 72% over the same period of the prior year.

Personalis, Inc. reported record quarterly revenue of $20.9 million in the first quarter of 2021, a 9% increase compared to the first quarter of 2020. The company's revenue from biopharma and all other customers, excluding VA MVP, grew 74% year-over-year.

Personalis, Inc. reported an 11% increase in revenue for the fourth quarter of 2020, reaching a record $20.2 million. The company's biopharma revenue was also strong, reaching a record high. The net loss for the quarter was $13.3 million, or $0.34 per share.

Personalis reported record revenues of $19.8 million for Q3 2020, a 15.5% increase compared to Q3 2019. The company's net loss was $9.5 million, or $0.27 per share. They also strengthened their balance sheet by raising $117.1 million through an equity financing.

Personalis reported record revenues of $19.5 million for the second quarter of 2020, a 23% increase compared to $15.8 million in the same period of the prior year. The VA MVP accounted for $14.8 million of total revenues, while biopharmaceutical and other customers contributed $4.7 million.

Personalis reported record revenues of $19.2 million for the first quarter of 2020, a 36% increase compared to the first quarter of 2019. Revenue growth was driven by increased volume for testing and analytical services provided to the VA MVP. The company reported a net loss of $9.1 million, or $0.29 per share.

Personalis reported record revenues of $18.2 million in the fourth quarter of 2019, a 38% increase compared to the same period in the prior year. The growth was primarily driven by an increase in volume for testing and analytical services provided to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP).